Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Dynamics during HCV Treatment in HCV/HIV Coinfection

Journal of Infectious Diseases

Volumn 188, Issue 10, 2003, Pages 1498-1507

  Torriani, Francesca J ^a,f   Ribeiro, Ruy M ^c,e   Gilbert, Tari L ^a   Schrenk, Uschi M ^d   Clauson, Marietta ^b   Pacheco, DeeDee M ^a   Perelson, Alan S ^c  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c LOS ALAMOS NATIONAL LABORATORY   (United States)

^d F HOFFMANN LA ROCHE LTD   (Switzerland)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A; RECOMBINANT INTERFERON; RIBAVIRIN;

ADULT; ARTICLE; BINDING KINETICS; CLEARANCE; CLINICAL ARTICLE; DRUG EFFICACY; HALF LIFE TIME; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; RNA ANALYSIS; VIRUS INFECTION; VIRUS LOAD;

ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; BIOPSY; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HIV-1; HUMANS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RIBAVIRIN; RNA, VIRAL; VIRUS REPLICATION;

EID: 0346874143     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/379255     Document Type: Article

References (48)

1. Palella FJ, Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338:853-60.
2. Goedert JJ, Eyster ME, Lederman MM, et al. End-stage liver disease in persons with hemophilia and transfusion-associated infections. Blood 2002; 100:1584-9.
3. Sulkowski MS, Mast EE, Seeff LB, Thomas DL. Hepatitis C virus infection as an opportunistic disease in persons infected with human immunodeficiency virus. Clin Infect Dis 2000; 30(Suppl 1):S77-84.
4. Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis 2002; 34:831-7.
5. Thomas DL. Hepatitis C and human immunodeficiency virus infection. Hepatology 2002; 36:S201-9.
6. McGovern B, Bica I. Risk of HAART therapy in hepatitis C. Hepatology 2002; 35:730.
7. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 32:492-7.
8. Monga HK, Rodriguez-Barradas MC, Breaux K, et al. Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 33:240-7.
9. Eyster ME, Fried MW, Di Bisceglie AM, Goedert JJ. Increasing hepatitis C virus RNA levels in hemophiliacs: relationship to human immunodeficiency virus infection and liver disease. Blood 1994; 84:1020-3.
10. Soto B, Sanchez-Quijano A, Rodrigo L, et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 1997; 26:1-5.
11. Sherman KE, Rouster SD, Horn PS. Comparison of methodologies for quantification of hepatitis C virus (HCV) RNA in patients coinfected with HCV and human immunodeficiency virus. Clin Infect Dis 2002; 35:482-7.
12. Daar ES, Lynn H, Donfield S, et al. Relation between HIV-1 and hepatitis C viral load in patients with hemophilia. J Acquir Immune Defic Syndr 2001; 26:466-72.
13. Matsiota-Bernard P, Vrioni G, Onody C, Bernard L, de Truchis P, Peronne C. Human immunodeficiency virus (HIV) protease inhibitors have no effect on hepatitis C virus (HCV) serum levels of HIV-HCV co-infected patients. Int J Antimicrob Agents 2001; 17:155-7.
14. Rutschmann OT, Negro F, Hirschel B, Hadengue A, Anwar D, Perrin LH. Impact of treatment with human immunodeficiency virus (HIV) protease inhibitors on hepatitis C viremia in patients coinfected with HIV. J Infect Dis 1998; 177:783-5.
15. Landau A, Batisse D, Piketty C, et al. Long-term efficacy of combination therapy with interferon-alpha 2b and ribavirin for severe chronic hepatitis C in HIV-infected patients. AIDS 2001; 15:2149-55.
16. Hayashi K, Fukuda Y, Nakano I, et al. Poor response to interferon treatment for chronic hepatitis C in human immunodeficiency virus-infected haemophiliacs. Haemophilia 2000; 6:677-81.
17. Soriano V, Rodriguez-Rosado R, Perez-Olmeda M, Romero M, Garcia-Samaniego J. Interferon plus ribavirin for chronic hepatitis C in HIV-infected patients. AIDS 2000; 14:2409-10.
18. Zylberberg H, Benhamou Y, Lagneaux JL, et al. Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report. Gut 2000; 47:694-7.
19. Causse X, Payen JL, Izopet J, Babany G, Girardin MF. Does HIV-infection influence the response of chronic hepatitis C to interferon treatment? A French multicenter prospective study. J Hepatol 2000; 32:1003-10.
20. Dieterich DT, Purow JM, Rajapaksa R. Activity of combination therapy with interferon alfa-2b plus ribavirin in chronic hepatitis C patients co-infected with HIV. Semin Liver Dis 1999; 19(Suppl 1):87-94.
21. + cell count. Infection 1998; 26:16-9.
22. Marriott E, Navas S, del Romero J, et al. Treatment with recombinant alpha-interferon of chronic hepatitis C in anti-HIV-positive patients. J Med Virol 1993; 40:107-11.
23. Boyer N, Marcellin P, Degott C, et al. Recombinant interferon-alpha for chronic hepatitis C in patients positive for antibody to human immunodeficiency virus. J Infect Dis 1992; 165:723-6.
24. Rodriguez-Torres M. Interferon alfacon-1 (Infergen) treatment for prior interferon alfa-2A or 2B non-responders coinfected with hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Hepatology 1999; 30:626A.
25. Sulkowski MS, Felizarta F, Slim J, Dieterich DT, Hudnall RF. Multicenter, randomized, open-label study of the safety and efficacy of interferon (IFN) alfa-2b plus ribavirin (RBV) for the treatment of hepatitis C virus (HCV) in HIV-infected persons [abstract ThPeC7496]. In: Abstracts of the XIV International AIDS Conference (Barcelona). Stockholm: International AIDS Society, 2002.
26. Chung R, Andersen J, Alston B, et al. A randomized, controlled trial of pegylated interferon alpha-2a with ribavirin vs. interferon alpha-2a with ribavirin for the treatment of chronic HCV in HIV co-infection: ACTG A5071 [abstract LB15]. In: Program and Abstracts of the 9th Conference on Retroviruses and Opportunistic Infections (Seattle). Alexandria, VA: Foundation for Retrovirology and Human Health, 2002.
27. Mallolas J, Laguno M, Murillas J, et al. Preliminary results of a randomized, controlled trial of pegylated interferon alpha 2-b with ribavirin vs interferon alpha 2-b with ribavirin for treatment of chronic HCV in HIV-1 patients [abstract LbPeB9022]. In: Abstracts of the XIV International AIDS Conference (Barcelona). Stockholm: International AIDS Society, 2002.
28. Rockstroh JK, Schulz C, Mauss S, Klausen G, Voigt E, Gölz J. Pegylated interferon-alpha and ribavirin therapy for hepatitis C in HIV-coinfected patients: 24 weeks results [abstract WePeB6025]. In: Abstracts of the XIV International AIDS Conference (Barcelona). Stockholm: International AIDS Society, 2002.
29. Perronne C, Carrat F, Sadr FB, et al. RIBAVIC trial (ANRS HC02): a controlled randomized trial of pegylated-interferon alfa-2b plus ribavirin vs interferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C in HIV co-infected patients: preliminary results [abstract LbOr16]. In: Abstracts of the XIV International AIDS Conference (Barcelona). Stockholm: International AIDS Society, 2002.
30. Bernasconi E, Magenta L, Vernazza P, et al. Interferon alfa-2a and ribavirin "low dose" for the treatment of HCV infection in HIV co-infected patients: an open-label, pilot study [abstract WePeB6037]. In: Abstracts of the XIV International AIDS Conference (Barcelona). Stockholm: International AIDS Society, 2002.
31. Sanchez Montero F. Efficacy and safety of therapy with interferon and ribavirin in HIV infected patients with chronic hepatitis C [abstract WePeB6018]. In: Abstracts of the XIV International AIDS Conference (Barcelona). Stockholm: International AIDS Society, 2002.
32. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.
33. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-82.
34. Hadziyannis SJ, Cheinquer H, Morgan T, et al. Peginterferon alfa-2a (40kD) (PEGASYS) in combination with ribavirin (RBV): efficacy and safety results from a phase III, randomized, double-blind, multicentre study examining effect of duration of treatment and RBV dose [abstract 1]. J Hepatol 2002; 36(Suppl 1):3.
35. Neumann AU, Lam NP, Dahari H, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998; 282:103-7.
36. Rosen HR, Ribeiro RR, Weinberger L, et al. Early hepatitis C viral kinetics correlate with long-term outcome in patients receiving high dose induction followed by combination interferon and ribavirin therapy. J Hepatol 2002; 37:124-30.
37. Zeuzem S, Herrmann E, Lee JH, et al. Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a. Gastroenterology 2001; 120:1438-47.
38. Zeuzem S, Schmidt JM, Lee JH, von Wagner M, Teuber G, Roth WK. Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon alfa on viral turnover. Hepatology 1998; 28:245-52.
39. Xu Z-X, Hoffman J, Patel I, Joubert P. Single dose safety, tolerability, and pharmacokinetic pharmacodynamics (PK/PD) following administration of ascending doses of pegylated interferon (PEG-IFN) and interferon alfa-2a to healthy subjects. Hepatology 1998; 28:702A.
40. Modi M, Fulton J, Buckmann D, et al. Clearance of pegylated (40kDa) interferon alfa-2a is primarily hepatic. Hepatology 2000; 32:371A.
41. Kessler HH, Clarici AM, Stelzl E, et al. Fully automated detection of hepatitis C virus RNA in serum and whole-blood samples. Clin Diagn Lab Immunol 2002; 9:1385-8.
42. Kawai S, Yokosuka O, Imazeki F, Saisho H, Mizuno C. Evaluation of the clinical usefulness of COBAS AMPLICOR HCV MONITOR assay (ver2.0): comparison with AMPLICOR HCV MONITOR assay (ver1.0) and HCV core protein level. J Med Virol 2002; 68:343-51.
43. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22:696-9.
44. Efron B, Tibshirani R. Bootstrap measures for standard errors, confidence intervals, and other measures of statistical accuracy. Stat Sci 1986; 1:54-77.
45. Sherman KE, Horn P, Rouster S, Peters M, Koziel M, Chung R. HCV RNA kinetic response to PEG-interferon and ribavirin in HIV co-infected patients [abstract 122]. In: Program and Abstracts of the 9th Conference on Retroviruses and Opportunistic Infections (Seattle). Alexandria, VA: Foundation for Retrovirology and Human Health, 2002:13.
46. Legrand E, Neau D, Galperine T, et al. CD4 T lymphocyte proliferative responses to hepatitis C virus (HCV) antigens in patients coinfected with HCV and human immunodeficiency virus who responded to anti-HCV treatment. J Infect Dis 2002; 186:302-11.
47. Hatzakis A, Gargalianos P, Kiosses V, et al. Low-dose IFN-alpha monotherapy in treatment-naive individuals with HIV-1 infection: evidence of potent suppression of viral replication. J Interferon Cytokine Res 2001; 21:861-9.
48. Rockstroh JK, Mudar M, Lichterfeld M, et al. Pilot study of interferon alpha high-dose induction therapy in combination with ribavirin for chronic hepatitis C in HIV-co-infected patients. AIDS 2002; 16:2083-5.